Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

Míreanna Comhchosúla

• Enhancement of Cellular Immunity in Melanoma Patients Immunized with a Peptide from MART-1/Melan A
  le: Cormier, Janice N., et al.
  Foilsithe: (1997)
• Culture of Melanoma Cells in 3-Dimensional Architectures Results in Impaired Immunorecognition by Cytotoxic T Lymphocytes Specific for Melan-A/MART-1 Tumor-Associated Antigen
  le: Ghosh, Sourabh, et al.
  Foilsithe: (2005)
• Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
  le: Zarour, Hassane M., et al.
  Foilsithe: (2000)
• Identification of an HLA-DPB1*0501 Restricted Melan-A/MART-1 Epitope Recognized by CD4(+) T Lymphocytes: Prevalence for Immunotherapy in Asian Populations
  le: Meng, Zhaoting, et al.
  Foilsithe: (2011)
• Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage
  le: Lupetti, Raffaella, et al.
  Foilsithe: (1998)